Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

26%

6 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Phase 3
6(35.3%)
Phase 1
4(23.5%)
Phase 2
3(17.6%)
N/A
3(17.6%)
Early Phase 1
1(5.9%)
17Total
Phase 3(6)
Phase 1(4)
Phase 2(3)
N/A(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07454941Enrolling By Invitation

Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics

Role: collaborator

NCT07383246Phase 3Recruiting

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

Role: collaborator

NCT06334783Phase 1Terminated

TIL for Patients With Advanced Solid Tumor

Role: collaborator

NCT04320979Phase 3Active Not Recruiting

Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients

Role: collaborator

NCT07321197Not ApplicableNot Yet Recruiting

Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC): A Randomized Clinical Trial

Role: collaborator

NCT07269574Not Yet Recruiting

Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance

Role: collaborator

NCT07201337Phase 3Recruiting

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Role: collaborator

NCT07182435Early Phase 1Not Yet Recruiting

Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors

Role: lead

NCT06241612Phase 3Recruiting

Individualized Elective Neck Irradiation in NPC Patients

Role: collaborator

NCT06781151Recruiting

A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB

Role: collaborator

NCT07040228Phase 1Recruiting

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Role: lead

NCT07026825Completed

Surgical Resection Enhances Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Study

Role: lead

NCT07002346Phase 3Not Yet Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: collaborator

NCT06990178Not ApplicableEnrolling By Invitation

Adaptive Neoadjuvant Therapy for Esophageal Cancer

Role: lead

NCT05955391Phase 2Active Not Recruiting

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Role: collaborator

NCT04517214Phase 2Active Not Recruiting

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT06712888Phase 3Recruiting

Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT06826885Recruiting

Safety and Efficacy of IMPT or IMRT for Breast Cancer

Role: collaborator

NCT06776770Phase 1Recruiting

A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer

Role: lead

NCT06776757Phase 1Recruiting

Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

Role: lead